Richard Quinton
YOU?
Author Swipe
View article: Testosterone-induced erythrocytosis: addressing the challenge of metabolic syndrome and widely prescribed SGLT2-inhibitor drugs
Testosterone-induced erythrocytosis: addressing the challenge of metabolic syndrome and widely prescribed SGLT2-inhibitor drugs Open
Testosterone is the cornerstone therapy for men with hypogonadism, and also treats any associated anaemia by promoting erythropoiesis. However, excessive doses cause erythrocytosis (raised red cell mass), especially if other risk factors a…
View article: Society for Endocrinology Clinical Practice Guideline for the Evaluation of Androgen Excess in Women
Society for Endocrinology Clinical Practice Guideline for the Evaluation of Androgen Excess in Women Open
Context Androgen excess is common in women and refers to clinical or biochemical evidence of elevated androgenic steroids such as testosterone. It is associated with underlying polycystic ovary syndrome in the majority of cases. However se…
View article: 7957 Delayed Diagnosis of Kallmann Syndrome: Journey from Patient to Advocate
7957 Delayed Diagnosis of Kallmann Syndrome: Journey from Patient to Advocate Open
Disclosure: N.D. Smith: None. R. Quinton: None. M. Lippincott: None. R. Balasubramanian: None. S.B. Seminara: None. A.A. Dwyer: None. Background: Rare diseases are associated with a ‘diagnostic odyssey’. Patients have difficulty finding ex…
View article: 12413 Reversal Of Congenital Hypogonadotropic Hypogonadism (CHH) In A Woman With A Heterozygous Inactivating Variant In GnRHR Gene
12413 Reversal Of Congenital Hypogonadotropic Hypogonadism (CHH) In A Woman With A Heterozygous Inactivating Variant In GnRHR Gene Open
Disclosure: S.W. Nyunt: None. M. Phylactou: None. K. Koysombat: None. J. Tsoutsouki: None. A.C. Yeung: None. M. Young: None. A. Newman: None. A.N. Comninos: None. Y. Mamoojee: None. N. Pitteloud: None. R. Quinton: None. W.S. Dhillo: None. …
View article: 12413 Reversal Of Congenital Hypogonadotropic Hypogonadism (CHH) In A Woman With A Heterozygous Inactivating Variant In GnRHR Gene
12413 Reversal Of Congenital Hypogonadotropic Hypogonadism (CHH) In A Woman With A Heterozygous Inactivating Variant In GnRHR Gene Open
Disclosure: S.W. Nyunt: None. M. Phylactou: None. K. Koysombat: None. J. Tsoutsouki: None. A.C. Yeung: None. M. Young: None. A. Newman: None. A.N. Comninos: None. Y. Mamoojee: None. N. Pitteloud: None. R. Quinton: None. W.S. Dhillo: None. …
View article: Current landscape of fertility induction in males with congenital hypogonadotropic hypogonadism
Current landscape of fertility induction in males with congenital hypogonadotropic hypogonadism Open
Congenital hypogonadotropic hypogonadism (CHH) is a rare reproductive disorder caused by deficient secretion or action of gonadotropin‐releasing hormone (GnRH) and is a hormonally treatable form of male infertility. Both pulsatile GnRH tre…
View article: The effects and safety of testosterone replacement therapy for men with hypogonadism: the TestES evidence synthesis and economic evaluation
The effects and safety of testosterone replacement therapy for men with hypogonadism: the TestES evidence synthesis and economic evaluation Open
Background Low levels of testosterone cause male hypogonadism, which is associated with sexual dysfunction, tiredness and reduced muscle strength and quality of life. Testosterone replacement therapy is commonly used for ameliorating sympt…
View article: Society for endocrinology guideline for understanding, diagnosing and treating female hypogonadism
Society for endocrinology guideline for understanding, diagnosing and treating female hypogonadism Open
Female hypogonadism (FH) is a relatively common endocrine disorder in women of premenopausal age, but there are significant uncertainties and wide variation in its management. Most current guidelines are monospecialty and only address prem…
View article: Editorial: Functional acquired hypogonadotropic hypogonadism in males
Editorial: Functional acquired hypogonadotropic hypogonadism in males Open
EDITORIAL article Front. Endocrinol., 31 January 2024Sec. Reproduction Volume 15 - 2024 | https://doi.org/10.3389/fendo.2024.1364634
View article: Gonadal tumour screening in XY gonadal dysgenesis
Gonadal tumour screening in XY gonadal dysgenesis Open
We read with great interest the recent paper by Hannema et al.1 that we found particularly illuminating in respect of our patient with 46XY gonadal dysgenesis, who continues to decline prophylactic gonadectomy. Disorders of sex development…
View article: Cost‐effectiveness of testosterone treatment utilising individual patient data from randomised controlled trials in men with low testosterone levels
Cost‐effectiveness of testosterone treatment utilising individual patient data from randomised controlled trials in men with low testosterone levels Open
Background Testosterone is safe and highly effective in men with organic hypogonadism, but worldwide testosterone prescribing has recently shifted towards middle‐aged and older men, mostly with low testosterone related to age, diabetes and…
View article: Outcomes and experiences of adults with congenital hypogonadism can inform improvements in the management of delayed puberty
Outcomes and experiences of adults with congenital hypogonadism can inform improvements in the management of delayed puberty Open
Patients with congenital hypogonadism will encounter many health care professionals during their lives managing their health needs; from antenatal and infantile periods, through childhood and adolescence, into adult life and then old age. …
View article: Symptomatic benefits of testosterone treatment in patient subgroups: a systematic review, individual participant data meta-analysis, and aggregate data meta-analysis
Symptomatic benefits of testosterone treatment in patient subgroups: a systematic review, individual participant data meta-analysis, and aggregate data meta-analysis Open
National Institute for Health and Care Research Health Technology Assessment Programme.
View article: OR25-05 Clinical Predictors Of Symptomatic Benefit In Men With Low Testosterone During Testosterone Treatment Compared With Placebo: Results Of Individual Patient And Aggregate Data Meta-analyses
OR25-05 Clinical Predictors Of Symptomatic Benefit In Men With Low Testosterone During Testosterone Treatment Compared With Placebo: Results Of Individual Patient And Aggregate Data Meta-analyses Open
Disclosure: J. Hudson: None. M. Cruickshank: None. R. Quinton: Speaker; Self; Bayer Schering Pharma, Besins. L. Aucott: None. F.C. Wu: None. M. Grossmann: None. S. Bhasin: None. P.J. Snyder: None. S. Ellenberg: None. T.G. Travison: None. G…
View article: Standardising the biochemical confirmation of adult male hypogonadism: A joint position statement by the Society for Endocrinology and Association of Clinical Biochemistry and Laboratory Medicine
Standardising the biochemical confirmation of adult male hypogonadism: A joint position statement by the Society for Endocrinology and Association of Clinical Biochemistry and Laboratory Medicine Open
Background Inter‐assay variation between different immunoassays and different mass spectrometry methods hampers the biochemical confirmation of male hypogonadism. Furthermore, some laboratories utilise assay manufacturer reference ranges t…
View article: Standardising the biochemical confirmation of adult male hypogonadism; a joint position statement by the Society for Endocrinology and Association of Clinical Biochemistry and Laboratory Medicine*
Standardising the biochemical confirmation of adult male hypogonadism; a joint position statement by the Society for Endocrinology and Association of Clinical Biochemistry and Laboratory Medicine* Open
Background: Inter-assay variation between different immunoassays and different mass spectrometry methods hampers the biochemical confirmation of male hypogonadism. Furthermore, some laboratories utilis eassay manufacturer reference ranges …
View article: Genetic architecture of self-limited delayed puberty and congenital hypogonadotropic hypogonadism
Genetic architecture of self-limited delayed puberty and congenital hypogonadotropic hypogonadism Open
Distinguishing between self limited delayed puberty (SLDP) and congenital hypogonadotropic hypogonadism (CHH) may be tricky as they share clinical and biochemical characteristics. and appear to lie within the same clinical spectrum. Howeve…
View article: Survey of endocrinologists managing recovery from anabolic androgenic steroid induced hypogonadism
Survey of endocrinologists managing recovery from anabolic androgenic steroid induced hypogonadism Open
Lay summary Anabolic steroids (also known as ‘steroids’) are banned drugs like testosterone, which make muscles bigger in men. These drugs are dangerous because they stop the testes from making natural testosterone and can cause heart atta…
View article: Insulin-like peptide 3 (INSL3) in congenital hypogonadotrophic hypogonadism (CHH) in boys with delayed puberty and adult men
Insulin-like peptide 3 (INSL3) in congenital hypogonadotrophic hypogonadism (CHH) in boys with delayed puberty and adult men Open
Background Delayed puberty in males is almost invariably associated with constitutional delay of growth and puberty (CDGP) or congenital hypogonadotrophic hypogonadism (CHH). Establishing the cause at presentation is challenging, with “red…
View article: OR25-5 Adverse Cardiovascular Events and Cause Mortality in Men During Testosterone Treatment: Individual Patient and Aggregate Data Meta-Analyses
OR25-5 Adverse Cardiovascular Events and Cause Mortality in Men During Testosterone Treatment: Individual Patient and Aggregate Data Meta-Analyses Open
Background The cardiovascular safety of testosterone treatment in low testosterone is widely acknowledged to be unclear. Testosterone increases haematocrit, thereby potentially increasing venous thromboembolism risk. The FDA lists cardiova…
View article: LBMON114 Enrichment Of Rare Sequence Variants In Genes That Communicate Metabolic Signals To The GnRH System In Hypothalamic Amenorrhea
LBMON114 Enrichment Of Rare Sequence Variants In Genes That Communicate Metabolic Signals To The GnRH System In Hypothalamic Amenorrhea Open
Introduction Functional hypothalamic amenorrhea (HA) is commonly associated with increased exercise or decreased caloric intake and often with stress. We have previously demonstrated an increased burden of rare sequence variants (RSVs) in …
View article: PMON258 Patient-Reported Outcomes for men with Hypogonadism and the Impact of Low Testosterone Levels: a review of measures
PMON258 Patient-Reported Outcomes for men with Hypogonadism and the Impact of Low Testosterone Levels: a review of measures Open
Background To better understand the impact of low testosterone treatments on men with hypogonadism, data on treatment efficacy and safety must be combined with patient-reported outcomes measurements (PROMs). Whether these objective tools c…
View article: <i>NOS1</i> mutations cause hypogonadotropic hypogonadism with sensory and cognitive deficits that can be reversed in infantile mice
<i>NOS1</i> mutations cause hypogonadotropic hypogonadism with sensory and cognitive deficits that can be reversed in infantile mice Open
The nitric oxide (NO) signaling pathway in hypothalamic neurons plays a key role in the regulation of the secretion of gonadotropin-releasing hormone (GnRH), which is crucial for reproduction. We hypothesized that a disruption of neuronal …